GeoVax to Present Pipeline Updates at H.C. Wainwright Investment Conference

GeoVax Labs, Inc. will present key updates on its clinical-stage vaccine and immunotherapy programs during the H.C. Wainwright 27th Annual Global Investment Conference in New York City from September 8-10, 2025. Chairman and CEO David Dodd will provide a company overview and discuss recent progress across multiple pipeline candidates, including the GEO-MVA Mpox/smallpox vaccine, GEO-CM04S1 COVID-19 vaccine, and Gedeptin® cancer therapy.

The presentation will highlight GEO-MVA, a next-generation MVA-based vaccine positioned to support global preparedness and stockpile strategies. The program recently received favorable Scientific Advice from the European Medicines Agency, potentially accelerating its development path. Based on recent EMA regulatory guidance, GeoVax anticipates progressing directly to Phase 3 clinical evaluation for this vaccine, omitting Phase 1 and Phase 2 trials.

GeoVax will also provide updates on GEO-CM04S1, its multi-antigen COVID-19 vaccine currently being evaluated in three Phase 2 clinical trials. The trials are assessing the vaccine across various patient populations, including immunocompromised individuals such as those with hematologic cancers, patients with chronic lymphocytic leukemia, and healthy adults who previously received mRNA vaccines. This addresses critical gaps in vaccine efficacy for vulnerable populations.

The company's oncology program featuring Gedeptin®, a gene-directed enzyme prodrug therapy for solid tumors, will also be discussed. The therapy recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers, with an upcoming Phase 2 trial planned for this indication.

GeoVax will emphasize how its MVA platform and U.S.-based continuous cell line manufacturing capabilities position the company to address critical gaps in vaccine supply diversification, pandemic readiness, and biosecurity. The webcast of Mr. Dodd's presentation will be available beginning at 7:00 am ET on September 8 through https://journey.ct.events/view/40d09ded-caa5-44ff-baf7-10795e9d5386.

These developments represent significant advancements in addressing unmet medical needs in infectious disease prevention and cancer treatment. The progress in GeoVax's pipeline could have substantial implications for global health security, particularly in preparing for future pandemics and improving outcomes for immunocompromised patients who remain vulnerable to current vaccine technologies.